San Diego, CA -- (SBWIRE) -- 06/24/2015 -- An investigation on behalf of investors of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) shares over potential securities laws violations by Dicerna Pharmaceuticals and certain of its directors and officers in connection certain financial statements was announced.

Investors who purchased shares of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation or call +1(858) 779 - 1554.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) concerning whether a series of statements by Dicerna Pharmaceuticals regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On June 10, 2015, Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced that it has filed a trade secret misappropriation lawsuit against Dicerna Pharmaceuticals, Inc. in the Superior Court of Middlesex County, Massachusetts. Alnylam Pharmaceuticals, Inc. said that by this lawsuit, it seeks to stop misappropriation by Dicerna Pharmaceuticals Inc of the company's confidential, proprietary, and trade secret information related to, among other things, GalNAc conjugate technology.

Those who purchased shares of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com